magi group

MAGI is concerned with research and diagnosis of rare genetic diseases. It has been operating since 2006 in Italy and abroad. Today it includes five centres including a medical genetics laboratory specialised in next generation sequencing in Bolzano, a medical genetics laboratory specialised in MLPA in Rovereto (Trento) and a genetic diseases information centre at San Felice del Benaco (Brescia). In the international context, MAGI has built a non-profit diagnostic centre in Tirana (Albania) and a spin-off laboratory at the University of Krasnoyarsk (Siberia). MAGI specialises in the development of genetic tests for little-known and rarely diagnosed Mendelian diseases; indeed, for some diseases MAGI is the only organisation in Italy and one of the few in Europe that can provide a genetic test. The organisation invests most of its profits in scientific research and training/information for healthcare personnel, including in developing countries, where MAGI offers a series of health services such as free genetic testing through Charity Program. MISSION MAGI’s objective has always been to offer diagnosis to patients through counselling and genetic testing for Mendelian diseases. MAGI is proud of the level of excellence it has achieved. It provides specialists with major diagnostic support. The implications of genetics not only concern patients, but their family as well, so that integrated multidisciplinary management is necessary. The availability of specific new therapies makes genetic tests increasingly necessary in diagnostic work-ups involving different specialists.

Lab Tech Support

Lab Tech Support helps scientists and laboratory analysts increase uptime, research & testing all while decreasing maintenance and repair cost of analytical instrumentation. Laboratory Service Provider with 20+ years of experience in mass spectrometry repair, maintenance and support. Whether your are located in the United States, Canada, Mexico, or Europe, our Service Engineers are available 24/7!

nova biologics, inc.

NOVA Biologics, Inc. is a global provider of biologic raw material intermediates to clinical laboratories, research organizations, and pharmaceutical and in-vitro manufacturers. We offer a range of serums and plasma, including disease state and patient sample materials. As well as human and animal-derived products for use in cell culture, IVD, and further manufacture of therapeutic injectable products. Nova Biologics, Inc. is dedicated to providing the highest quality biologic raw material intermediates to our diverse customer base in order to help meet the demanding needs and requirements of their organizations. We are committed to establishing strategic, long-term relationships with our valued customers and partners by providing them with secure procurement of products at competitive prices in a timely manner. Our vision is to continue to facilitate supply and manufacturing partnerships allowing NOVA to expand our product and service capabilities. Our products include diagnostic serums and plasma, human serum albumin, human gamma globulin, disease plasmas, clinical samples, and human and animal-based materials. Nova is the sales representative for Octapharma excipient albumin to the biotech and pharmaceutical industry worldwide.

Servatus Ltd

We are a biopharmaceutical research and production company, based on the Sunshine Coast, Queensland. Established in 2012, we research, develop and produce high-quality, innovative, medical grade biopharmaceuticals based on the latest scientific research. Servatus has two drug research platforms: Engineered proteins for the treatment of autoimmune diseases, and microbial biotherapeutics for the treatment of inflammatory conditions and bacterial infections. Our protein research focuses on improving specific characteristics of existing therapeutic proteins. We carefully select proteins with clear clinical utility, and through rational redesign of key features, we improve bioavailbility and biological potency. We then rapidly clone and express the proteins in amounts suitable for clinical use, thus providing faster, more effective treatment of chronic auto immune diseases, such as rheumatoid arthritis and psoriasis, with fewer undesirable side effects. In parallel with our protein work, we also develop live microbial biotherapeutic treatments for microbiome-associated conditions, including but not limited to inflammatory bowel disease (IBD), arthritis, atopic dermatitis, and gastrointestinal infections (for example, C. diff and H.pylori infections). We utilise bacterial strains that have not been widely employed previously, but have demonstrated bioactive properties in the latest scientific research. These bacteria have been shown to inhibit pathogenic bacterial growth and infection, modulate immune responses, and regulate inflammatory signals. Bacterial candidates are developed to act directly at specific sites to treat specific ailments and diseases. Servatus currently holds patents for numerous microbial biotherapeutics and engineered proteins for autoimmune disease treatments Servatus Ltd derives its name from the patron saint St Servatus, a 4th century churchman and diplomat, who was invoked as a saint for his healing powers for a range of ailments. #biotech

entos pharmaceuticals

Entos Pharmaceuticals Inc. is a clinical-stage genetic medicines company. A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. At Entos, we develop next generation genetic medicines using our proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of nucleic acid into target cells through direct fusion.